These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 9218839)

  • 1. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.
    Zlotta AR; Drowart A; Huygen K; De Bruyn J; Shekarsarai H; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Mascart F; Simon J; Schulman CC; Van Vooren JP
    Clin Exp Immunol; 1997 Jul; 109(1):157-65. PubMed ID: 9218839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?
    Zlotta AR; van Vooren JP; Huygen K; Drowart A; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Simon J; Schulman CC
    Eur Urol; 2000 Apr; 37(4):470-7. PubMed ID: 10765079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy.
    Zlotta AR; Drowart A; Van Vooren JP; Shekarsarai H; De Cock M; Pirson M; Palfliet K; Jurion F; Simon J; Schulman CC; Huygen K
    J Urol; 1998 Jun; 159(6):1885-91. PubMed ID: 9598481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
    Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
    Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.
    van der Meijden AP; Steerenberg PA; van Hoogstraaten IM; Kerckhaert JA; Schreinemachers LM; Harthoorn-Lasthuizen EJ; Hagenaars AM; de Jong WH; Debruijne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1989; 28(4):287-95. PubMed ID: 2784716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and DnaK proteins requires cross-linking with antigen.
    Barrios C; Georgopoulos C; Lambert PH; Del Giudice G
    Clin Exp Immunol; 1994 Nov; 98(2):229-33. PubMed ID: 7955527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming.
    Barrios C; Lussow AR; Van Embden J; Van der Zee R; Rappuoli R; Costantino P; Louis JA; Lambert PH; Del Giudice G
    Eur J Immunol; 1992 Jun; 22(6):1365-72. PubMed ID: 1601031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder.
    Ardelt PU; Kneitz B; Adam P; Reiss C; Kocot A; Fensterle J; Chen L; Pasqualini R; Arap W; Gerharz EW; Riedmiller H
    Cancer; 2010 Feb; 116(3):600-9. PubMed ID: 19957324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycobacterial heat-shock proteins as carrier molecules.
    Lussow AR; Barrios C; van Embden J; Van der Zee R; Verdini AS; Pessi A; Louis JA; Lambert PH; Del Giudice G
    Eur J Immunol; 1991 Oct; 21(10):2297-302. PubMed ID: 1680693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies to human heat shock protein (hsp)60 may be induced by Escherichia coli groEL.
    Handley HH; Yu J; Yu DT; Singh B; Gupta RS; Vaughan JH
    Clin Exp Immunol; 1996 Mar; 103(3):429-35. PubMed ID: 8608642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD.
    Barrios C; Tougne C; Polla BS; Lambert PH; Del Giudice G
    Clin Exp Immunol; 1994 Nov; 98(2):224-8. PubMed ID: 7955526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lack of relationship between serum content of MBL, sCD14, anti-PPD and anti-Hsp65 IgG and ingestion of Mycobacterium bovis BCG bacilli by phagocytes.
    Paziak-Domańska B; Bonar A; Kowalewicz-Kulbat M; Klink M; Kowalski M; Karhukorpi J; Karttunen R; Jurkiewicz M; Rózalska B; Rudnicka W
    Arch Immunol Ther Exp (Warsz); 2002; 50(5):337-44. PubMed ID: 12455868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guérin immunotherapy.
    Mano R; Zilber S; Di Natale RG; Kedar D; Lifshitz DA; Yossepowitch O; Baniel J; Margel D
    Urol Oncol; 2018 Dec; 36(12):531.e9-531.e17. PubMed ID: 30337218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
    Winters WD; Lamm DL
    Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of antigen-specific CD4+ HLA-DR-restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein.
    Ab BK; Kiessling R; Van Embden JD; Thole JE; Kumararatne DS; Pisa P; Wondimu A; Ottenhoff TH
    Eur J Immunol; 1990 Feb; 20(2):369-77. PubMed ID: 1690136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.
    Stassar MJ; Vegt PD; Steerenberg PA; van der Meijden AP; Meiring HD; Dessens-Kroon M; Geertzen HG; den Otter W
    Urol Res; 1994; 22(3):177-84. PubMed ID: 7992464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of IgG responses to mycobacterial antigens.
    Pilkington C; Costello AM; Rook GA; Stanford JL
    Arch Dis Child; 1993 Dec; 69(6):644-9. PubMed ID: 8285775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and humoral immune responses to mycobacterial stress proteins in experimental pulmonary tuberculosis.
    Bartow RA; McMurray DN
    Tuber Lung Dis; 1997; 78(3-4):185-93. PubMed ID: 9713651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults.
    Black GF; Weir RE; Chaguluka SD; Warndorff D; Crampin AC; Mwaungulu L; Sichali L; Floyd S; Bliss L; Jarman E; Donovan L; Andersen P; Britton W; Hewinson G; Huygen K; Paulsen J; Singh M; Prestidge R; Fine PE; Dockrell HM
    Clin Diagn Lab Immunol; 2003 Jul; 10(4):602-11. PubMed ID: 12853392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.